According to Seattle Genetics, the LIV-1 (SLC39A6) expression level was maintained after hormone therapy at both primary and metastatic sites; however, it was elevated in patients with triple-negative breast cancer. This evidence concerns the gene SLC39A6 and triple-negative breast carcinoma.